ArticleFrontiers in immunology2024

Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.

Zicheng Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.